Lynparza has been approved in the US for first-line maintenance therapy of BRCA-mutated advanced ovarian cancer.
News
28 cases of polio-like AFP seen in 2018
2018 has seen 28 cases of a polio-like illness called acute flaccid paralysis (AFP), more than double the typical yearly amount of less than ten, found in primarily children.
Dengvaxia approved for dengue in EU
The European Commission has granted marketing authorisation for Sanofi’s dengue vaccine Dengvaxia.
New cervical cancer test 100% effective
A new cervical cancer test has been found to detect 100% of cervical cancers, according to a report published in The International Journal of Cancer.
Vertex to submit Orkambi, Symkevi to SMC
Vertex has revealed that it will be submitting its cystic fibrosis medicines Orkambi and Symkevi to the Scottish Medicines Consortium for appraisal, following “constructive discussions” with the Scottish government.
Make sure you don’t run out of time – start the entry process now!
The PharmaTimes International Clinical Researcher of the Year will close for entry on the 31st January 2019 – make sure you allow yourself enough time to work through the process.
Bruntwood to make £10M life science investment
Bruntwood SciTech has announced a £10 million investment into the life sciences sector, in the form of 50,000 square feet of office space and laboratory facilities in Alderley Park, Cheshire.
NIHR’s Clinical Research Network links with PAREXEL in the North West
The National Institute for Health Research has announced a new partnership agreement signed between the Clinical Research Network: North West Coast and PAREXEL.
EU & NICE authorise MSD’s Keytruda for stage III melanoma
MSD’s Keytruda has been given a green light for use within the EU as an adjuvant treatment for stage III melanoma, and has also been made available on the NHS.
GSK and Pfizer to create consumer healthcare JV
GlaxoSmithKline and Pfizer have unveiled plans to combine their consumer health businesses into a new world-leading Joint Venture worth around £9.8 billion.
Nearly half of CCGs rated ‘requires improvement’ or ‘inadequate’
A new report from the National Audit Office has found that In 2017-18, 42% (87 of 207) of Clinical Commissioning Groups (CCGs) were rated either ‘requires improvement’ or ‘inadequate’, with as little as 10% rated as ‘outstanding’.
Alkermes and Biogen announce new MS drug application for FDA
Alkermes has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for experimental multiple sclerosis (MS) drug diroximel fumarate.
Havas Lynx Group recruitment drive creates 60 new jobs
Havas Lynx Group has created as many as 60 new jobs with its largest ever recruitment drive.
75 projects to receive £1bn in NHS services upgrade
Health and Social Care secretary Matt Hancock has announced that £1 billion of funding will go to as many as 75 projects across England to upgrade facilities and treat more patients, including mental health and new integrated care services in the community.
Private firms receive £26m from tight NHS budget
The British Medical Association (BMA) has reported that private consultancy firms have been paid at least £26 million by the NHS as part of plans to reorganise the health service.
